PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 943-948

  Ren, Yu ^a   Zhou, Xuan ^a   Qi, Yanbin ^a   Li, Guolan ^a   Mei, Mei ^a   Yao, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

catenin pathway; Breast cancer; LY294002; Phosphatidyl inositol 3 kinase AKT pathway; PTEN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOVIRUS VECTOR; ALANYLALANYLCYSTYLTHREONYLGLYCYLCYSTYLTHREONYLCYSTYLALANYLCYSTYLCYSTYLGLYCYLGLYCYLALANYLALANYLTHREONINE; BETA CATENIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RECOMBINANT ENZYME; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR TCF 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; MONOTHERAPY; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; ENZYME ACTIVATION; FEMALE; GENE THERAPY; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865344510     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1856     Document Type: Article

References (20)

1. Ferté C, André F and Soria JC: Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 7: 367-380, 2010.
2. Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054-1063, 2011.
3. Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P and Broggini M: Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 71: 4573-4584, 2011.
4. Chen Y, Wang BC and Xiao Y: PI3K: A potential therapeutic target for cancer. J Cell Physiol 227: 2818-2821, 2011.
5. Ghayad SE and Cohen PA: Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 5: 29-57, 2010.
6. Liu W, Zhou Y, Reske SN and Shen C: PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res 28: 3613-3619, 2008.
7. Heikkinen T, Greco D, Pelttari LM, Tommiska J, Vahteristo P, Heikkila P, Blomqvist C, Aittomaki K and Nevanlinna H: Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res 13: R130, 2011.
8. Carraway H and Hidalgo M: New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6: 219-224, 2004.
9. Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S and Roberts LR: Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 30: 1522-1528, 2010.
10. Shin JY, Kim JO, Lee SK, Chae HS and Kang JH: LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 13: 425, 2010.
11. Fujiwara M, Izuishi K, Sano T, Hossain MA, Kimura S, Masaki T and Suzuki Y: Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 27: 76-84, 2008.
12. Yang S, Xiao X, Meng X and Leslie KK: A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6: e26343, 2011.
13. Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, et al: Preclinical activity of the rational combination of Selumetinib (AZD6244) in combination with Vorinostat in KRAS mutant colorectal cancer models. Clin Cancer Res 18: 1051-1062, 2012.
14. Sun HW, Wu C, Tan HY and Wang QS: Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway. Hepatogastroenterology 59: 115-116, 2011.
15. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, et al: Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. Breast Cancer Res 13: R125, 2011.
16. Miller TW, Rexer BN, Garrett JT and Arteaga CL: Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13: 224, 2011.
17. Dozza B, Smith MA, Perry G, Tabaton M and Strocchi P: Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells. J Neurochem 89: 1224-1232, 2004.
18. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M and Bosenberg M: β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20: 741-754, 2011.
19. Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, Qiu Y, Xie Q and Ge J: Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation. Cancer Sci 103: 181-190, 2011.
20. Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S and Li L: Cooperation between both Wnt/β-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 25: 1928-1942, 2011.